Randomized, double-blind, placebo-controlled study of F17464, a preferential D3 antagonist, in the treatment of acute exacerbation of schizophrenia

Neuropsychopharmacology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles